---
document_datetime: 2024-03-20 13:22:35
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_en.pdf
document_name: vidprevtyn-beta-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.5193424
conversion_datetime: 2025-12-15 02:37:09.166212
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<div style=\"page-break-after: always\"></div>

--¹

After mixing, one dose (0.5 mL) contains 5 micrograms of SARS-CoV-2 spike protein (B.1.351 strain)* and is adjuvanted with AS03. AS03 adjuvant is composed of squalene (10.69 milligrams), DLα -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams). *produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda.

<!-- image -->

<!-- image -->

MA (EU) number (Invented) name Strength Pharmaceutical Form EU/1/21/1580/001 VidPrevtyn Beta --¹ Solution and emulsion for emulsion for injection --¹ Medicinal product no longer a

## Route of Administration

Intramuscular use

## Immediate Packaging

Antigen solution: vial (glass); Adjuvant emulsion: vial (glass)

## Content (concentration)

Antigen solution: 2.5 ml; Adjuvant emulsion: 2.5 ml (10 doses)

Pack size

10 multidose vials + 10 multidose vials (100 doses)